Introduction Intentional drug overdose (IDO) is a significant public health problem. Concerns about the misuse of gabapentinoids, i.e. pregabalin and gabapentin, including their consumption in IDO have grown in recent years. This paper examines the trends in the prevalence of gabapentinoids taken in IDO, the profile of individuals taking them, and associated overdose characteristics. Methods Presentations to emergency departments involving IDO, recorded by the National Self-Harm Registry Ireland between 1 January 2007 and 31 December 2015 were examined. Data items included patient demographics, drug names, total tablet quantity consumed and alcohol involvement. Results Gabapentinoids were involved in 2115 (2.9%) of the 72,391 IDOs recorded. Presentations involving a gabapentinoid increased proportionally from 0.5% in 2007 to 5.5% in 2015. The majority of IDOs involving a gabapentinoid were made by females (59.9%), with over one-third (37.2%) involving alcohol. Compared with IDOs involving other drugs, presentations with a gabapentinoid were made by persons who were older (median 37 vs. 32 years) and involved a significantly greater median quantity of tablets (30 vs. 21, p B 0.001), with over one-quarter (27.4%) of these involving the ingestion of 50 tablets or more. Admission to hospital was significantly more common following IDOs with a gabapentinoid compared with those without (49.4% vs. 41.4%, p B 0.001). Conclusions This study identified the increasing use of gabapentinoids in IDO, describing the profile and overdose characteristics of presentations. It is important for clinicians to exercise vigilance while prescribing gabapentinoids, including being aware of other medications that their patients may have access to. Our findings support the need for routine monitoring for signs of misuse among those prescribed gabapentinoids.
Introduction
Intentional drug overdose (IDO) is a significant public health issue, associated with psychiatric comorbidity, repeat self-harm, and suicide [1] [2] [3] [4] . Most common among females and those aged under 45 years, IDO accounts for between 65 and 85% of all hospital-based self-harm presentations, frequently involving multiple drug use and alcohol consumption [1, 2, [5] [6] [7] [8] . Psycholeptic, psychoanaleptic and analgesic drugs currently represent the most frequently reported drug types involved in IDO [1, 2, [9] [10] [11] . Gabapentinoids, i.e. pregabalin and gabapentin, are licensed for the treatment of epilepsy, postherpetic neuralgia, fibromyalgia and neuropathic pain associated with diabetes or spinal cord injury and generalised anxiety disorder (pregabalin only) [12] [13] [14] [15] [16] . Despite their availability by prescription only, concerns about the misuse of pregabalin and gabapentin continue to increase [17] [18] [19] [20] [21] [22] .
Studies have found associations between pregabalin or gabapentin consumption and multiple drug use [23] , accidental death [24] and overdose [22, [25] [26] [27] [28] [29] [30] . The physiological implications of overdose with a gabapentinoid alone vary and are largely exacerbated by the combined consumption of other drugs in overdose [31] . Research shows that individuals who have ingested an antiepileptic in overdose require more intensive medical and psychiatric intervention and a longer hospital stay when compared with those who have consumed other drugs [32] . Regarding fatalities, 427 deaths recorded between 2012 and 2016 in England and Wales involved a gabapentinoid, with these drugs increasingly acting as a contributory factor in mortality across this time period [21, 33] . In Ireland, pregabalin-related deaths increased by 86% between 2013 and 2014 [34] .
A recent systematic review examined the extent, characteristics and impact of gabapentinoid misuse, and found a 2% prevalence of abuse in the general population, which extended to 68% for opioid abusers, contributing to a documented increase in the abuse of these drugs [17] . Nixon et al. reported that 3.4% of overdose admissions in one hospital in Edinburgh, Scotland, between 2000 and 2007 involved a type of antiepileptic drug [32] . Across a similar timeframe, a 25% increase in the frequency of antiepileptic drugs used in overdose in the US was reported [29] . Gabapentinoid misuse, and pregabalin misuse in particular, appears to be frequent among illegal drug users [17, 23, 35] and addiction treatment patients, of which a minority have been prescribed the drug [21, 27, 36, 37] . Factors associated with the misuse of gabapentinoids include having a prescription of drugs used to treat mental illness [38] , a history of substance abuse, particularly opioids [17, 28] , and psychiatric comorbidities [17] .
Parallel to the abuse potential of gabapentinoids is the expansion in the range of indications for which they can be used [12] [13] [14] , a growing illegal market [23] and an increase in the recorded prescribing of antiepileptic drugs, including gabapentinoids [32, 39, 40] . Evidence regarding the misuse of pregabalin has resulted in the scheduling of the drug in the US [41] , its listing as a new recreational psychoactive substance within the European Union in 2010 [42] , the issuing of prescribing guidelines for the drug in England and Northern Ireland [19, 43] , and proposals to reclassify pregabalin and gabapentin as controlled drugs in the UK [44] .
Empirical studies and guidelines focussed on the emerging issue of gabapentinoid misuse recommend continued surveillance of the frequency and trends in its use [18, 26, 27, 37] . The aim of this study was to examine trends in the consumption of pregabalin and gabapentin in IDO, using data from the National Self-Harm Registry Ireland. Data on IDOs recorded by the Registry during the period 2007-2015 were examined to describe the profile of individuals who had taken a gabapentinoid in IDO and associated overdose characteristics.
Methods

National Self-Harm Registry Ireland
The National Self-Harm Registry Ireland monitors the occurrence of hospital-treated self-harm. As of 2006, the Registry has collected self-harm data from all 36 acute hospitals across the Republic of Ireland. This study involves all presentations of IDO involving pregabalin and gabapentin for the period 1 January 2007 to 31 December 2015. Data collection is carried out by trained Data Registration Officers (DROs), and cases of self-harm are independently identified and recorded by DROs using a combination of manual and electronic checks of emergency department presentations. A full description of data items and procedures of the Registry has been provided by Perry et al. [7] .
Data Items
Cases of IDO include those with International Classification of Diseases, Tenth Revision (ICD-10) codes of X60-X64 (overdose of drugs and medicaments). Presentations of accidental overdose with prescribed medications intended to treat specific illnesses or with illegal drugs used for recreational purposes (without evidence of intent to selfharm), as well as poisonings of undetermined intent (ICD-10 codes Y10-Y19), were not included. In addition, cases of self-poisoning involving other agents such as chemicals and alcohol-only self-poisoning cases were excluded. Drug names and the quantity of tablets ingested in IDO, involving up to 13 drugs, are captured in the Registry via self-reported information from the patient, ambulance service records, hospital medical records and toxicology reports where present. Drugs taken in IDO are categorised according to their Anatomical Therapeutic Chemical (ATC) classification code [45] . Cases of overdose with the ingestion of 'pregabalin' or 'lyrica' (ATC code N03AX16) and 'gabapentin' or 'neurontin' (ATC code N03AX12) were included in this study. Alcohol involvement prior to or during the act of IDO is captured by the DROs through hospital case notes, as recorded on registration or by the attending clinician, or if present in toxicology reports. The number of tablets reported refers to the total number of tablets consumed in each IDO act. In the context of this paper, multiple drug use refers to the use of two or more drugs other than alcohol registered as being involved in a presentation.
Statistical Analysis and Reporting
Statistical analyses were conducted using IBM SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). We applied a threshold of p\0.05 (two-sided) for statistical significance, using Chi-square tests to analyse group differences and also to test for linearity. Mann-Whitney U tests were used to examine data that was not normally distributed. In compliance with the National Self-Harm Registry Ireland regulations, event counts below a value of 5 were not disclosed to protect the identity of individuals. The type of drug, or drugs, taken was missing or recorded as 'unknown' for 8.2% (5957) of all IDOs, thus drugs taken was known for 91.8% (66,434) of all presentations. Additional missing data are cited in Table 1 In total, 2115 presentations (3.2%), for which the drugs taken were known, involved the ingestion of a gabapentinoid. The majority of these gabapentinoid IDOs involved pregabalin (2.9%, 1953). Gabapentin was involved in 201 (0.3%) presentations. Across the study period, the proportion of all IDOs involving a gabapentinoid increased continually from 0. Online resource 1 provides a summary of the demographic characteristics of males and females presenting to hospital following IDO with a gabapentinoid. The majority of these IDOs were made by females (59.9% vs. 40.1%), and the age of persons presenting ranged between 12 and 82 years. The median age for all presentations was 37 years, with the majority falling within the age range of 26-54 years (74.6%, 1577) ( Table 1) . Alcohol was involved in over one-third of presentations (37.2%, 787) ( Table 1 ). The majority of presentations involved multiple drug use, in which individuals consumed a gabapentinoid and another drug in IDO (52.4%, 1109).
The median number of total tablets taken per IDO involving a gabapentinoid was 30 (interquartile range , and over one-quarter of presentations were the result of ingesting 50 tablets or more per presentation (27.4%, 414) . Approximately one in every ten presentations involving a gabapentinoid resulted in the patient leaving before being seen, or refusing to be admitted (10.8%, 229) ( Table 1) . Table 1 compares the profile of individuals presenting with IDOs involving and not involving a gabapentinoid. Persons presenting following an IDO with a gabapentinoid were older with a higher median age, compared with those engaging in IDO with other drugs (37 vs. 32 years). Presentations with a gabapentinoid involved a significantly greater quantity of tablets per act when compared with IDOs without pregabalin or gabapentin (30 vs. 21 ; degrees of freedom = 1, p\0.001). Over one-quarter of presentations with a gabapentinoid (27.4%, 414) involved over 50 
Discussion
Examining data from a national self-harm surveillance system, we found an increasing trend for consumption of pregabalin and gabapentin in IDOs between 2007 and 2015, with the majority involving females and those in the early middle-aged group. We found that the number of tablets consumed in gabapentinoid presentations was significantly greater compared with presentations using other types of drugs. The misuse of gabapentinoids via their consumption in IDOs has increased tenfold across the time period studied (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . This increase in the misuse of antiepileptics, including gabapentinoids, in overdose mirrors that observed in similar studies and surveillance systems [17, 22, 25, 29] . Through this research, we have identified that ingestion of gabapentinoids in IDO is associated with being female and of early middle-age, which informs the international literature examining the use of antiepileptics in overdose and the particular risk profile involved [27, 32] . Females more commonly enact IDO, more often engage in repeat IDO and are more likely to consume an antiepileptic drug in overdose, when compared with males [1, 32, 46] . Antiepileptic drug use in Europe is more common in females, presenting a possible explanation for their more frequent use in female IDO [47] . Persons presenting with IDOs involving gabapentinoids were significantly older than those who did not take the drug in overdose, which could be reflective of prescribing patterns, although information on the gender and age profile of those prescribed gabapentinoids in Ireland is not available for comparison.
Alcohol was present in 37% of gabapentinoid IDOs and significantly more frequent among males. While alcohol involvement was slightly lower in IDOs involving gabapentinoids, this remains an issue for concern as alcohol consumption combined with IDO is associated with overdose repetition [46, 48] and impacts significantly on patient treatment [49] and hospital resources [50] . Furthermore, alcohol consumption in overdoses with prescription drugs can increase the lethality of a particular act [49] . In our study, we found that admission to hospital was significantly greater following presentations with a gabapentinoid, compared with IDOs without these drugs. Previous research has shown that individuals who have ingested an antiepileptic in overdose require more intensive medical and psychiatric intervention and longer hospital stay when compared with those who have consumed other drugs [32] , signposting important consequences in terms of hospital resource utilisation. One explanation for these outcomes could be that the clinical seriousness of IDO with a gabapentinoid is elevated when it is taken in conjunction with another drug [51] , which is evident in over half of our study sample. Perhaps the clinical implications of IDO with a gabapentinoid are related to drug combinations consumed, although further research is necessary to assess this hypothesis.
Another consideration when examining IDO characteristics is the number of tablets consumed, as the ingestion of excessive numbers of tablets is associated with higher suicidal intent [52] , the need for more intensive care and a more serious health outcome [53] . In this study, IDOs with a gabapentinoid involved a greater quantity of total tablets per presentation compared with IDOs with other drugs. The reasons for and impacts of this are underexamined, although access to the drug could be a factor. The choice of drug taken in IDO is predominantly determined by its ready accessibility [11, 54] . One Danish study found that having a prescription of drugs used to treat mental illness was associated with excessive pregabalin consumption [38] , a finding that echoes other research linking population-level availability of a drug to the frequency and trends of its involvement in overdose [9, 10, [55] [56] [57] . This may be explained by overprescribing and a lack of patient adherence to recommended advice. It also offers an opportunity for intervention in terms of means restriction, which is one with proven efficacy and effectiveness [58] .
To date, research has underlined the importance of careful prescribing for psychotropic drugs. Against the backdrop of significant clinical and resource utilisation implications of overdose with a gabapentinoid, the present study underpins the importance of vigilant and considered prescribing practices for gabapentinoids to ensure that these are not readily accessible to individuals at risk of IDO. Considerate prescribing of gabapentinoids needs to be mindful of an individual's medical history and to continuously review for potential misuse or dependence. In relation to the policy implications of this research, our findings provide an evidence base to support suicide prevention efforts nationally and internationally [59] . Furthermore, these findings should be considered by those responsible for implementing prescribing guidelines and recommendations, and should be integrated into training and mental health awareness programmes for healthcare professionals.
In this study, we used robust data from the National Self-Harm Registry Ireland, which is internationally unique to this field and is endorsed by the World Health Organization [60] . However, there are several limitations to this study. Considering the criteria used to define IDO cases, which does not provide insight into the measure of intent of an IDO, it is not possible to uniquely identify particular cases that are those of a suicide attempt or a case of drug abuse or misuse. Information collected on drugs used and quantity of tablets consumed in IDO was self-reported by the presenting individual, which may be subject to inaccuracy; however, these data are supplemented by ambulance service records, hospital medical records and toxicology reports where present. From hospital records, we cannot determine the given indication for drugs used. Information on the drug dose and drug source, including whether or not it was prescribed to the particular individual, is also not currently collected.
Conclusion
The present study has quantified the increasing trend of IDO involving pregabalin and gabapentin, and provides insight into the profile of persons engaging in intentional overdose with these drugs. Given the growing extent of the misuse of gabapentinoids, prescribers should be aware of high-risk populations, and routinely monitor for signs of their misuse.
